Table 4.
Baseline characteristics by biomarker availability
| All episodes | Incomplete information | Both biomarkers available | |
| n = 2754 | n = 974 | n = 1780 | |
| Clinical presentation | |||
| Age, years (IQR) | 68 (58–75) | 67 (56–75) | 68 (59–75) |
| Female gender, n (%) | 1199 (44) | 472 (48) | 728 (41) |
| CHA2DS2-VASc (IQR) | 3 (1–4) | 2 (1–4) | 3 (2–4) |
| Comorbidities | |||
| Heart failure, n (%) | 628 (22.8) | 228 (23.4) | 400 (22.5) |
| Hypertension, n (%) | 1696 (61.6) | 548 (56.3) | 1151 (64.7) |
| DM, n (%) | 401 (14.6) | 120 (12.3) | 282 (15.8) |
| TIA, n (%) | 46 (1.7) | 11 (1.1) | 35 (2.0) |
| Stroke, n (%) | 141 (5.1) | 49 (5.0) | 92 (5.2) |
| CAD, n (%) | 458 (16.6) | 132 (13.6) | 326 (18.3) |
| Previous MCI, n (%) | 219 (8.0) | 56 (5.7) | 163 (9.2) |
| PAD, n (%) | 107 (3.9) | 25 (2.6) | 82 (4.6) |
| Hyperlipidaemia(%) | 840 (30.5) | 277 (28.4) | 565 (31.7) |
| Current smoker, n (%) | 130 (4.7) | 37 (3.8) | 93 (5.2) |
| COPD, n (%) | 256 (9.3) | 100 (10.3) | 156 (8.8) |
| Medication | |||
| Beta-blockers, n (%) | 1133 (41.1) | 382 (39.2) | 751 (42.2) |
| Amiodaron) | 477 (17.3) | 138 (14.2) | 339 (19.0) |
| VKA, n (%) | 766 (27.8) | 249 (25.6) | 517 (29.0) |
| NOAC, n (%) | 355 (12.9) | 120 (12.3) | 237 (13.3) |
| Diuretics, n (%) | 567 (20.6) | 180 (18.5) | 389 (21.9) |
CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; hs-TnT-sensitive troponin t, MCI, myocardial infarction;NOAC, new oral anticoagulant; NT-proBNP, N-terminal pro-brain natriuretic peptide; PAD, peripheral artery disease; VKA, vitamin K antagonist.